What's in Deutsches Herzzentrum Muenchen's pipeline?

Deutsches Herzzentrum Muenchen has 8 drugs in our index: 7 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Deutsches Herzzentrum Muenchen's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Sanofi, Azienda Policlinico Umberto I, Beijing Chao Yang Hospital, Beijing Suncadia Pharmaceuticals Co., Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/deutsches-herzzentrum-muenchen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Deutsches Herzzentrum Muenchen — Portfolio Competitive Intelligence Brief

Deutsches Herzzentrum Muenchen pipeline: 7 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ORSIRO	ORSIRO	marketed			Other
Abrupt Clopidogrel Interruption	Abrupt Clopidogrel Interruption	marketed
oral anticoagulation	oral anticoagulation	marketed
Iomeprol 350	Iomeprol 350	marketed
Abciximab + UFH	Abciximab + UFH	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor	Cardiovascular
Un-fractionated heparin	Un-fractionated heparin	marketed	Anticoagulant	Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect inhibition)	Cardiovascular
Clopidogrel Tapering	Clopidogrel Tapering	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 platelet receptor	Cardiovascular

Therapeutic area mix

Cardiovascular · 3
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Sanofi · 2 shared drug classes
Azienda Policlinico Umberto I · 1 shared drug class
Beijing Chao Yang Hospital · 1 shared drug class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
Boston Scientific Corporation · 1 shared drug class
CCRF Consulting Co., Ltd. · 1 shared drug class
Beijing Anzhen Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Deutsches Herzzentrum Muenchen:

Cite this brief

Drug Landscape (2026). Deutsches Herzzentrum Muenchen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/deutsches-herzzentrum-muenchen. Accessed 2026-05-16.